G
Giulia Pasello
Researcher at University of Padua
Publications - 158
Citations - 2672
Giulia Pasello is an academic researcher from University of Padua. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 19, co-authored 113 publications receiving 1597 citations.
Papers
More filters
Journal ArticleDOI
Effects of Sulfonylureas on Tumor Growth: A Review of the Literature
TL;DR: Preclinical evidence of second-generation sulfonylureas effects on tumor growth is reviewed, to clarify the potential mechanisms of action, and to identify possible metabolic targets for patient selection.
Journal Article
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.
Laura Bonanno,Marco Schiavon,Giorgia Nardo,Roberta Bertorelle,Laura Bonaldi,Alessandra Galligioni,Stefano Indraccolo,Giulia Pasello,Federico Rea,Adolfo Favaretto +9 more
TL;DR: In a group of clinically selected patients, EGFR and KRAS analysis was able to define distinct molecular subsets of lung adenocarcinoma.
Journal ArticleDOI
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment
TL;DR: The present review gives a complete landscape about the role of MDM2 in cancer pathogenesis, prognosis and treatment, with particular focus on Malignant Pleural Mesothelioma.
Journal ArticleDOI
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
Carmine Pinto,Paolo Andrea Zucali,Maria Pagano,Federica Grosso,Giulia Pasello,Marina Chiara Garassino,Marcello Tiseo,Hector Soto Parra,Francesco Grossi,Federico Cappuzzo,Filippo de Marinis,Paolo Pedrazzoli,Maria Bonomi,Letizia Gianoncelli,Matteo Perrino,Armando Santoro,F. Zanelli,Candida Bonelli,Antonio Maconi,Stefano Frega,Erika Gervasi,Luca Boni,Giovanni Luca Ceresoli +22 more
TL;DR: The RAMES trial as mentioned in this paper evaluated the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in patients with pretreated malignant pleural mesothelioma.
Journal ArticleDOI
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
Giovanni Luca Ceresoli,Federica Grosso,Paolo Andrea Zucali,Manlio Mencoboni,Giulia Pasello,C. Ripa,D. Degiovanni,Matteo Simonelli,Andrea Bruzzone,C Dipietrantonj,E. Piccolini,Giordano D. Beretta,Adolfo Favaretto,Laura Giordano,Armando Santoro,M. Botta +15 more
TL;DR: Non-epithelioid histology, age ⩾75 years, advanced IMIG stage and presence of comorbidities according to CCI were significant prognostic factors in elderly patients with MPM.